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Abstract  
 
The peripheral nervous system has an intrinsic capability to regenerate that is 
crucially related to the ability of Schwann cells (SC) to create a permissive environment, 
e.g. through production of regeneration promoting neurotrophic factors. Survival, 
proliferation, migration and differentiation of SC into a myelinating phenotype during 
development and after injury is regulated by different Neuregulin1 (NRG1) isoforms. 
This study investigates the expression of different NRG1 isoforms and of their ErbB 
receptors in distal rat median nerve samples under regenerating conditions after a mild 
(crush) and more severe (end-to-end repair) injury and under degenerating condition. The 
expression of the NRG1/ErbB system was evaluated at mRNA and protein level and 
demonstrated to be specific for distinct and consecutive phases following nerve injury and 
regeneration or the progress in degeneration. For the first time we present a detailed 
analysis of expression profiles not only of soluble and transmembrane NRG1 isoforms, but 
also of alpha and beta as well as type a, b, and c isoforms. The results of mRNA and 
protein expression pattern analyses were related to nerve ultrastructure changes 
evaluated by electron microscopy.   
In particular, transmembrane NRG1 isoforms are differentially regulated under 
regeneration and degeneration conditions. Soluble NRG1 isoforms alpha and beta, as well 
as type a and b, are strongly up-regulated during axonal regrowth, while type c NRG1 
isoform is down-regulated. This is accompanied by an up-regulation of ErbB receptors.  
This accurate regulation suggests that each molecule plays a specific role that 
could be clinically exploited to improve nerve regeneration. 
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Introduction  
 
Following an injury to the Peripheral Nervous System (PNS), nerve fibres retain the 
capacity to regenerate. However, a complete repair is rarely achieved, leading to a partial 
or total loss of motor, sensory and autonomic functions. 
Peripheral nerve degeneration and regeneration involve complex processes such 
as morphological and physiological modifications, variation in cellular composition and 
changes in gene expression and signal transduction. Investigating these mechanisms on a 
molecular level is therefore important to identify factors promoting successful nerve repair, 
especially axonal regrowth, remyelination, and target reinnervation.  
It is well known that peripheral glia cells, Schwann cells (SC), are the crucial 
element to create an environment supportive for axonal regeneration. Thus recognizing 
signals that control the SC response in nerve regeneration and degeneration is of great 
interest. One of the most important factors regulating SC action is Neuregulin1 (NRG1), 
which is not only involved in survival, proliferation, differentiation, and migration of SC 
during development, but is also required for axon guidance by SC and remyelination after 
nerve injury in adulthood (Taveggia et al., 2010; Fricker & Bennett, 2011; Pereira et al., 
2012; Salzer, 2012; Gambarotta et al., 2013; Heermann & Schwab, 2013; Gambarotta et 
al., 2014b). 
 The gene coding for NRG1 is very large and through the use of different promoters 
and alternative exon splicing, a vast variety of distinct transcripts and protein isoforms are 
generated (Adlkofer & Lai, 2000). According to their structure and signalling activity, NRG1 
isoforms can be classified as soluble or transmembrane. Soluble isoforms (type I/II) are 
produced as pro-NRG1 anchored to the cell membrane. Following a proteolytic cleavage, 
a soluble fragment is released into the extracellular environment for paracrine or autocrine 
signalling. Transmembrane isoforms (type III) signal in a juxtacrine manner. The NRG1 
isoforms can be further divided into alpha and beta isoforms, according to the presence of 
a small domain downstream the EGF like domain, and into type a, b, and c isoforms, 
according to the exon present in the C-terminal tail (Falls, 2003). 
NRG1 signalling is transduced in SC by ErbB2/ErbB3 heterodimers (Garratt et al., 
2000; Yarden & Sliwkowski, 2001). NRG1 isoforms have different spatiotemporal patterns 
of expression providing different roles during myelination and nerve repair. When 
expressed by axons, transmembrane NRG1 determines their myelination status and the 
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myelin sheath thickness, both during development and nerve regeneration (Michailov et 
al., 2004; Taveggia et al., 2005). In contrast, autocrine signalling via soluble NRG1 is not 
necessary for developmental myelination, but for SC survival, redifferentiation and 
remyelination after nerve injury (Stassart et al., 2013).   
In this study we elucidate changes in mRNA and protein expression of NRG1, ErbB 
receptors, and myelin basic protein during early peripheral nerve regeneration and 
degeneration. Therefore, adult rat median nerves were crushed or end-to-end repaired 
(regenerating conditions) or left unrepaired after transection (degenerating condition) and 
distal nerve segments were subjected to expression analysis. Additionally, nerve 
morphology analysis revealed the morphological correlates.  
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Material and Methods 
Ethical standards 
All procedures were approved by the Bioethics Committee of the University of 
Torino, by the Institutional Animal Care and Use Committee of the University of Torino, 
and by the Italian Ministry of Health, in accordance with the European Communities 
Council Directive of 24 November 1986 (86/609/EEC). 
 
Surgery 
In this study a total of 64 adult female Wistar rats (Harlan Laboratories), weighing 
approximately 200 g, were used. Animals were housed in plastic cages with free access to 
food and water; their room was maintained at constant temperature and humidity under 
12–12 h light/dark cycles.  
For mRNA and protein analysis, a total of 52 rats were randomly divided into 4 
experimental groups according to the nerve injury/repair: (i) in the crush injury group 
(axonotmesis), median nerves were bilaterally crushed at the mid humerus level with a 
non-serrated clamp, as previously described (Ronchi et al., 2009); (ii) for end-to-end repair 
(neurotmesis) median nerves were bilaterally transected at the same position as in (i) and 
the proximal and distal nerve ends were immediately reconnected with two epineurial 
sutures (9/0); (iii) in the degenerating nerve group, median nerves were bilaterally 
transected at the same location as in (i) and (ii) and left unrepaired (to prevent 
regeneration, the proximal stumps were sutured to the major pectoralis muscle); (iv) finally, 
in the control group (n=7), animals were left uninjured.  
For electron microscopy analysis (nerve morphology), 5 additional rats were 
subjected to condition (i) and 5 rats to condition (iii). Finally, for in vitro nerve culture, 2 rats 
were used.  
During surgery, rats were deeply anesthetized with Tiletamine and Zolazepam 
(Zoletil) i.m. (3 mg/kg). Adequate measures were taken to minimize pain and discomfort 
during the post-operative period.  
Rats were sacrificed by lethal i.m. injection of Tiletamine and Zolazepam at different 
time-points after injury/repair/degeneration. For mRNA and protein analysis, n=3 animals 
per time-point were analysed. For morphological analysis, n=1 animal per time-point was 
sacrificed. Time points analysed were: 1, 3, 7, 14 and 28 days. Nerve segments 
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(approximately 10mm) distally to the lesion site were collected. Control nerves were 
collected from healthy animals.  
 
In vitro nerve culture  
 For in vitro nerve degeneration, each median nerve was divided into two 5-mm 
segments and cultured for 1 day in high glucose DMEM (Sigma) supplemented with 100 
units/ml penicillin, 0.1 mg/ml streptomycin, 1 mM sodium pyruvate, 2 mM L-glutamine, 
10% heat-inactivated foetal bovine serum (FBS, Invitrogen). Nerves were grown at 37°C in 
a 5% CO2 atmosphere saturated with H2O. 
 
RNA isolation, cDNA preparation and quantitative real-time PCR 
Total RNA was isolated using the TRIzol Reagent (Invitrogen) according to the 
manufacturer’s instructions. 0.75 μg total RNA were subjected to a reverse transcriptase 
(RT) reaction in a 20 μl reaction volume containing: 1x RT-Buffer (Invitrogen), 0.1 μg/μl 
bovine serum albumin (BSA), 0.5 μM dNTPs; 7.5 μM random decamers (Invitrogen); 40 U 
RIBOlock (Fermentas) and 200 U SuperScript III Reverse Transcriptase (Invitrogen). The 
reaction was performed at 25°C 10 min, at 50°C 90 min, at 70°C 15 min. Quantitative real-
time PCR was performed using an ABI Prism 7300 (Applied Biosystems, Life 
Technologies Europe BV, Monza, Italy) detection system. cDNA was diluted 12.5 fold in 
nuclease-free water and 5 μl (corresponding to 15ng starting RNA) were analysed in a 20 
μl reaction volume, containing 1 x iTaq Universal SYBR Green Supermix (BioRad) and 
300 nM forward and reverse primers. Dissociation curves were routinely performed to 
check for the presence of a single peak corresponding to the required amplicon. Analysis 
was performed in technical and biological triplicate.  
The data from the real-time PCR experiments were analysed using the ΔΔCt 
method for the relative quantification. The threshold cycle number (Ct) values of both the 
calibrator and the samples of interest were normalized to the geometric average of two 
endogenous housekeeping genes: ANKRD27 (Ankyrin repeat domain 27) and RICTOR 
(RPTOR Independent Companion Of MTOR, Complex 2) (Gambarotta et al., 2014a). As 
calibrator the average of uninjured nerves was used.  
Primers were designed using Annhyb software (http://www.bioinformatics. 
org/annhyb/) and synthesized by Invitrogen (Life Technologies Europe BV, Monza, Italy). 
Primers sequences are reported in Table I.  
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All normalized relative quantitative data are depicted in the results section as -ΔΔCT 
instead of 2–ΔΔCT because in this way it is possible to appreciate both up-regulation 
(ranging between 0 and + ∞) and down-regulation (ranging between 0 and - ∞), while, 
when data are expressed as the more commonly used 2–ΔΔCT, the down-regulation is 
graphically compressed (ranging between 0 and +1). 
 
Total protein extraction and western blot analysis 
Total proteins were extracted using the TRIzol Reagent (Invitrogen) after RNA 
extraction, according to the manufacturer’s instructions. In the final passage, the protein 
pellet was re-suspended in boiling Laemli buffer (2.5% SDS, 0.125M TrisHCl pH6.8). 
Protein concentration was determined using the Bicinchoninic Acid assay kit (Sigma) on 
1:4 diluted proteins to avoid detergent interference. Proteins (50µg/sample) were routinely 
resolved by 8% SDS-PAGE; for the analysis of NRG1 isoforms 4-15 % precast gels were 
used (Bio-Rad). Western blot analysis was carried out as previously described 
(Gambarotta et al., 2004). Primary antibodies used were: anti-ErbB1 (#sc-03), anti-ErbB2 
(#sc-284), anti-ErbB3 (#sc-285), anti-NRG1 type “a” C-terminal (#sc-348), (1:1000, all 
Santa Cruz, USA); anti-NRG1 type III N-terminal (#AB5551, 1:1000, Chemicon 
International, USA); anti-p-AKT (#4051), anti-AKT (#9272), anti-p-ERK (#9106), anti-ERK 
(#9102) (1:1000, all Cell Signaling Antibodies, MerckMillipore Europe); a pool of anti-MBP 
was used (#SMI 94 and SMI 99, 1:4000, Covance, Princeton, NJ, USA); anti-GAPDH 
(#4300, 1:20000, Ambion, ThermoFischer Scientific Inc, Europe); anti-β-actin (#A5316, 
1:4000, Sigma, Germany); secondary antibodies used were horseradish peroxidise linked 
anti-rabbit (#NA934) and anti-mouse (#NA931) (both 1:40000, GE Healthcare Life 
Sciences, Europe). 
Two housekeeping genes, actin and GAPDH, were shown in the western blot 
panels because, as discussed in a previous paper focused on housekeeping gene stability 
at mRNA level (Gambarotta et al., 2014a), it is difficult to find a gene whose expression is 
not influenced by the injury. 
 Proteins previously extracted from primary cultured SC (Gnavi et al., 2015) were 
used as a control for NRG1 expression. 
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Resin embedding and electron microscopy analysis 
 Nerve samples were fixed by immediate immersion in 2.5% glutaraldehyde in 0.1 M 
phosphate buffer (pH 7.4) for 4 to 6 hours at 4° C. Samples were then post-fixed in 2% 
osmium tetroxide for 2 hours and dehydrated in passages in ethanol from 30% to 100%. 
After two passages of 7 min each in propylene oxide and o/n in a 1:1 mixture of propylene 
oxide and Glauerts’ mixture of resins, specimens were embedded in Glauerts’ mixture of 
resins (made of equal parts of Araldite M and the Araldite Harter, HY 964). In the resin 
mixture, 0.5% of the plasticizer dibutylphthalate was added. For the final step, 2% of 
accelerator 964 was added to the resin in order to promote the polymerization of the 
embedding mixture.  
Ultra-thin sections (70nm thick) were cut with an Ultracut UCT ultramicrotome 
(Leica Microsystems, Wetzlar, Germany) starting from the distal end and stained with 
saturated aqueous solution of uranyl acetate and lead citrate. Sections were analysed 
using a JEM-1010 transmission electron microscope (JEOL, Tokyo, Japan) equipped with 
a Mega-View-III digital camera and a Soft-Imaging-System (SIS, Münster, Germany) for 
the computerized acquisition of the images. 
 
Statistical methods  
Gene expression analysis was carried out in technical triplicates of biological 
triplicates. Data statistical analysis (one-way ANOVA with Bonferroni’s post hoc) was 
performed using SPSS software. Data discussed in the paper refer to the comparison 
between the gene expression at different time points and the gene expression in the 
healthy nerve. Statistical analysis shown in the figures refers to the comparison among the 
three experimental models at the different analysed time points, as indicated in the figure 
legends. 
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Results 
 
At the different time points after injury (1, 3, 7, 14, and 28 days) mRNA and protein 
expression levels of ErbB receptors and different NRG1 isoforms were examined by 
quantitative real-time PCR (qRT-PCR) and western blot analysis in median nerve 
segments obtained from healthy animals or distal nerve segments obtained from the three 
experimental groups: i) crush injury, ii) end-to-end repair, iii) degenerating nerve.  
 
ErbB mRNAs are differentially regulated between regenerating and degenerating 
conditions  
ErbB1 mRNA expression does not change significantly in the crush and 
degenerating groups following injury, whereas in the end-to-end group an up-regulation 
(1.73 ± 0.11 fold) is detectable at day-14 (p=0.008). At day-28 mRNA levels are 
comparable to control condition in the three experimental models (crush: 1.28 ± 0.21 fold; 
end-to-end: 1.45 ± 0.24 fold; degenerating nerve: 0.99 ± 0.16). Statistical analysis 
revealed significant effects related to the type of injury (Figure 1). 
 
ErbB2 mRNA expression level demonstrates a strong down-regulation from day-1 
after injury under regenerating conditions (crush: 0.29 ± 0.06 fold, p<0.001; end-to-end: 
0.19 ± 0.03 fold, p<0.001) that lasts until day-28 (crush: 0.17 ± 0.04 fold, p=0.034; end-to-
end: 0.51 ± 0.10 fold, p<0.001). Under degenerating conditions ErbB2 expression does not 
change significantly. Significant differences among groups are detectable (Figure 1).  
 
ErbB3 mRNA expression is strongly decreased 1 day after injury (crush: 0.42 ± 
0.12, p=0.009; end-to-end: 0.35 ± 0.09, p=0.005; degenerating nerve: 0.54 ± 0.14, 
p=0.053), followed by an increase until day-7 in all experimental groups.  
Under regenerating conditions ErbB3 expression returns to control levels at day 28 
(crush: 1.14 ± 0.19 fold; end-to-end repair: 1.61 ± 0.33 fold). Under degenerating 
conditions the up-regulation remains almost stable until day 28 after injury (2.84 ± 0.82, 
p=0.001). Statistical analysis showed significant differences related to the type of injury 
(Figure 1). 
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ErbB4 mRNA expression was also analysed, but in the peripheral nerve it is barely 
detectable (data not shown). 
 
mRNA expression levels of NRG1 soluble isoforms are strongly up-regulated immediately 
after nerve injury  
The mRNA expression of soluble isoforms of NRG1 (NRG1 type I/II, mostly 
expressed by SC), shows a similar time course pattern in all experimental models: 
expression is highly increased (p<0.001) immediately after injury, peaking at day-1 after 
injury (crush: 24.12 ± 6.02 fold; end-to-end: 26.75 ± 0.33 fold; degenerating nerve: 33.03 ± 
6.03 fold). Then, the expression level decreases and returns to control values at day-28  
after the injury. Intriguingly, in the degenerating group NRG1 type I/II expression is still 
higher at day-3 compared to control conditions (8.21 ± 2.10 fold, p=0.002) Statistical 
analysis revealed no significant effects among injury types (Figure 2).  
 Soluble and transmembrane NRG1 can be either the isoform alpha or beta, 
according to the exon present in the C-terminal region of the EGF-like domain. The 
expression of mRNA encoding for NRG1 alpha and NRG1 beta demonstrated a different 
regulation pattern.  
Expression of NRG1 alpha is strongly up-regulated immediately after nerve injury in 
all experimental groups (p<0.001) displaying a peak at day-1 after injury (crush: 34.76 ± 
12.45 fold; end-to-end: 36.80 ± 2.82 fold; degenerating nerve: 15.24 ± 3.73 fold). Under 
regenerating conditions, the expression level decreases towards control level which is 
reached and stabilized from day-14 to day-28 after injury. Under degenerating conditions a 
decrease of expression reaching control values at day-7 after injury is detectable, 
remaining not significantly different until day-28. Significant differences among the groups 
are not detectable (Figure 2).  
Expression of NRG1 beta mRNA is also strongly up-regulated (p<0.001) peaking at 
day-1 after injury (crush: 12.18 ± 3.35 fold; end-to-end: 16.47 ± 0.37 fold; degenerating 
nerve: 13.55 ± 2.66 fold). In the following, the mRNA expression in the crush group 
reaches control expression levels already at day-3; in the end-to-end group mRNA 
expression decreases below control levels at day-7 (0.30 ± 0.12 fold, p=0.046) and day-14 
(0.13 ± 0.00, p=0.002); finally, under degenerating conditions NRG1 beta expression is still 
up-regulated at day-3 (3.74 ± 1.06, p=0.043) and down-regulated at day-7 (0.17 ± 0.07, 
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p=0.001). Statistical analysis showed no significant differences related to the type of injury 
(Figure 2). 
 
mRNA expression level of NRG1 transmembrane isoforms is regulated under regenerating 
conditions 
Transmembrane NRG1 is known to be mainly expressed by axons, whose cell 
bodies are in the dorsal root ganglia and in the ventral horn of the spinal cord where 
mRNA transcription occurs. For this reason, in the healthy and injured nerves NRG1 type 
III transcript level is low, with high expression variability. Expression levels in the 
degenerating nerve do not change significantly, whereas they decrease under 
regenerating conditions at day-14 in the crush group (0.10 ± 0.01 fold, p=0.001) and at 
day-28 in the end-to-end group (0.07 ± 0.02 fold, p<0.001). Statistical analysis revealed 
significant effects related to the type of injury (Figure 2). 
 
mRNA expression level of NRG1 type a, type b and type c isoforms is deeply regulated 
following nerve injury  
Finally, all NRG1 isoforms, both soluble and transmembrane, can be classified as 
type a, b, or c isoforms, according to the exon present in the C-terminal part of the protein 
(Falls, 2003; Mei & Xiong, 2008).  
A strong expression of the type a isoform is detectable at day-1 after injury 
(p<0.001) in all experimental models (crush: 7.92 ± 0.35 fold; end-to-end: 11.32 ± 0.47 
fold; degenerating nerve: 13.85 ± 3.12 fold). From day-3 the expression returns to control 
values in the three experimental models, although under degenerating conditions this 
decrease is slower (at day-3: 1.76 ± 0.33 fold, p=0.070) (Figure 3).  
The expression pattern of the type b NRG1 isoform is similar to type a, with a peak 
at day-1 from the injury (p<0.001) in three injury models (crush: 7.76 ± 1.83 fold; end-to-
end: 11.33 ± 3.20 fold; degenerating nerve: 15.55 ± 3.09 fold). Under regenerating 
conditions the expression returns to control values from day-3 onward, whereas under 
degenerating conditions the expression is still high at day-3 (2.38 ± 0.31, p=0.011) (Figure 
3). 
Finally, the mRNA expression of the type c NRG1 isoform is strongly down-
regulated after injury, remaining low until the end of the observation period (crush: 0.23 ± 
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0.12 fold, p=0.016; end-to-end: 0.05 ± 0.01 fold, p<0.001; degenerating nerve: 0.25 ± 0.02 
fold, p=0.050) (Figure 3). 
Statistical analysis revealed significant effects related to the type of injury for NRG1 
type a, type b and type c, as shown in Figure 3. 
 
NRG1/ErbB mRNA expression patterns depend on the expression by cells resident to the 
nerve  
To investigate whether the deep changes observed at day-1 after injury are 
dependent on cells resident to the nerve or on cells invading it after injury, such as e.g. 
macrophages, healthy median nerve samples were put into degeneration in vitro for 1 day 
and the mRNA expression level was analysed and compared to fresh healthy control 
levels. As depicted in Figure 4, all analysed genes demonstrated an expression pattern 
similar to the expression pattern detected in vivo under degenerating conditions.   
 
ErbB receptor protein expression is strongly up-regulated at day-7 after injury 
The protein expression level of ErbB1, ErbB2 and ErbB3 receptors and of some 
NRG1 isoforms following nerve injury was assessed by western blot analysis of proteins 
obtained from the same samples analysed for mRNA expression levels.  
 
ErbB1 protein (Figure 5) is expressed in the healthy control nerve and, following 
injury, its expression initially decreases. At day-3 after injury, however, protein expression 
is already increased and remains almost stably up-regulated until day-28 under 
regenerating conditions. Under degeneration conditions ErbB1 expression level 
demonstrated a constantly increasing up-regulation until the end of the observation period. 
Protein expression levels do not reflect the changes detected for mRNA expression levels 
(Figure 1). This is most evident under the degenerating conditions.  
 
ErbB2 shows a protein expression pattern (Figure 5) which is again strongly 
different from the mRNA expression pattern (Figures 1): ErbB2 protein is barely detectable 
in healthy control nerve samples or until day-3 after injury, while its expression is strongly 
up-regulated at day-7 to day-14, followed by a slight decrease until day-28. ErbB2 protein 
expression levels are similar under regenerating and degenerating conditions, while 
mRNA expression is differentially regulated and never displaying an up-regulation.  
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ErbB3 protein (Figure 5) is expressed in healthy control nerve samples and strongly 
down-regulated until it is almost undetectable at day-3 after injury. At day-7, however, 
similar to ErbB2 protein, ErbB3 protein expression levels are strongly up-regulated and 
remain high 14 and 28 days after injury. The ErbB3 protein expression levels reflect the 
changes detected for ErbB3 mRNA expression (Figure 1). 
 
The PI3K and the ERK MAP kinase pathways are activated following nerve injury   
Two signal transduction pathways were analysed under regenerating and 
degenerating conditions: the phosphatydil-inositol-3 kinase (PI3K), and the ERK MAP 
kinase pathways.  
A basal expression level of phosphorylated AKT phosphorylation is detectable in 
healthy nerve samples and an increased expression can be appreciated 7 days after injury 
in the end-to-end repaired and degenerating distal nerve samples. In Figure 5, the band 
corresponding to the phosphorylated AKT is detectable between two unspecific bands. Its 
identification was possible by comparison with the band corresponding to the total AKT 
protein.  
Phosphorylated ERK 1/2 protein (Figure 5) is barely detectable in healthy nerve 
samples and strongly up-regulated at day-1 after injury where it remains high until day-7 
prior to its slow decrease until day-28 after injury. At day-3 in the end-to-end group and at 
day-3 and day-7 in the degenerating nerve ERK seems less phosphorylated, but this is 
due to a lower amount of protein extract loaded for these samples, as can be verified from 
total ERK analysis. 
 
Protein levels of different NRG1 isoforms are differentially regulated after injury  
The analysis of NRG1 expression is a very difficult aim, both at mRNA and protein 
level, because several isoforms exist, which are characterized by the combination of exons 
shared in part with other isoforms (Figure 6). We analysed NRG1 expression using two 
specific antibodies: AB5551, directed to the cytoplasmic N-terminus shared by all 
transmembrane type III isoforms, and sc-348, directed to the type “a” cytoplasmic C-
terminus. The “a” exon is one of the three possible known C-termini (which can be a, b, or 
c) downstream the transmembrane and the cytoplasmic domain common to all 
transmembrane NRG1 isoforms (soluble type I/II pro-proteins, transmembrane type III, 
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alpha, beta isoforms) except the β3 isoforms, which lack this region and are produced as 
“ready-to-use” proteins (Falls, 2003; Mei & Xiong, 2008). 
In Figure 6A, the entire western blot for NRG1 proteins is shown, because the 
AB5551 antibody recognizes several bands which seem to be regulated following nerve 
injury. In particular, we focused on two bands.   
The 100 kDa band, which seems to be expressed not only by axons but also by SC, 
appears between day-3 and day-7 after injury and its expression is switched off 28 days 
after injury under regenerating conditions while it remains highly expressed under 
degenerating conditions. This band seems to reflect the expression of a full length type III 
NRG1, isoform b or c, due to its high molecular weight. It is likely not reflecting expression 
of full length type III NRG1 isoform type “a”, because it is not detectable with the antibody 
sc-348 (Figure 6B).  
With AB5551, another interesting band can be detected at approximately 75 kDa. 
The molecular weight of this band increases slightly after injury suggesting that this small 
increase could be due to a switch between ADAM17/TACE and BACE1 proteolytic 
cleavage of the detected type III NRG1. As illustrated in Figure 6C, when analysing type III 
NRG1 protein expression with an antibody recognizing the N-terminus of the protein, the 
product after cleavage by the α-secretase ADAM17/TACE (the α-N-terminal fragment/α-
NTF), has a lower molecular weight than the product cleaved off by the β-secretase 
BACE1 cleavage, the β-NTF. On the contrary, when the expression of the type III NRG1 
protein is analysed with an antibody recognizing the C-terminus of the protein, the product 
of the ADAM17/TACE cleavage (the α-C-terminal fragment/α-CTF) has a higher molecular 
weight than the product of the BACE1 cleavage (β-CTF), as previously elegantly shown by 
others (Fleck et al., 2013).  
Regarding the expression levels of the NRG1 α-NTF and β-NTF, the healthy nerve 
expresses only the α-NTF (Figure 6A).  
Under regenerating conditions after mild injury (crush) both α-NTF and β-NTF are 
weakly expressed at day-1 and exclusively β-NTF at day-3. At day-7 and day-14 after 
injury α-NTF is strongly and β-NTF weakly expressed with the expression of the latter 
being eliminated at day-28 (resembling the status of a healthy nerve segment). 
Under regenerating conditions after a more severe injury (end-to-end repair), α-NTF  
is still expressed in the distal nerve segment at day-1 after injury, then completely 
disappears until the end of the observation period (day-28), when it is expressed again 
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(resembling the expression pattern of a healthy nerve segment). At day-3 and day-7 after 
end-to-end repair the β-NTF band is only barely detectable in regenerating distal nerve 
segments, and its expression increases at day-14.  
Under degenerating conditions, however, α-NTF expression disappears at day-1 
after injury, while β-NTF is observed over the complete observation period, during which 
no regeneration occurs.  
Lower molecular weight bands (around 50 kDa) were also detected, whose 
expression seems to increase after injury in the three experimental models.  
The same nerve specimen, as subjected to AB5551 western blot analysis, were 
subjected to analysis with an antibody (sc-348) recognizing a 75k Da band corresponding 
to the C-terminal fragment (CTF) of type “a” NRG1 isoforms (Figure 6B). An expression 
increase of CTF was detectable after injury. This was followed by a decrease in protein 
levels under regenerating conditions (crush: at day-7; end-to-end: at day-28), while in the 
degenerating nerve the expression level remained stably elevated.   
The CTF band detectable with sc-348 antibody does not show alpha and beta 
fragments like the NTF band, thus suggesting that this CTF derives mainly from the 
cleavage of type I/II NRG1 isoforms and not from type III NRG1 isoforms.  
 
Distal nerve morphology displays different phases under regenerating and degenerating 
conditions 
The ultrastructure of distal nerve segments was investigated by electron microscopy 
analysis (Figure 7). In particular, we focused on regenerating (crush) and degenerating 
nerves, assuming that end-to-end-repaired distal nerve morphology will resemble that of 
the crushed nerve just with a delay.  
One day after injury (Figure 7, A, F), the general organization of the median nerve 
morphology is preserved under both regenerating and degenerating conditions and similar 
to that of a healthy control nerve, just some signs of fibre degeneration are already 
detectable, like e.g. partially de-compacted myelin sheaths surrounding collapsed axons.  
Three days after injury (Figure 7, B, G), first signs of Wallerian degeneration are 
clearly detectable in both the regenerating and the degenerating condition. Nerve fascicles 
display dispersed fibres with an increased amount of connective tissue between them; 
some fibres show detachment and vacuolization of myelin lamellae, causing axolemma 
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exposure. However, many fibre profiles still present a normal ultrastructure in both crushed 
and degenerating nerves. 
Seven days after injury (Figure 7, C, H), almost all nerve fibres display degeneration 
in both experimental groups. The nerve samples contain mainly collapsed axons with 
disintegrated myelin sheaths. Dedifferentiated SC with phagocytic properties are 
frequently detected by the numerous vacuoles in their cytoplasm. 
Fourteen days after injury (Figure 7, D, I) first differences between the distal nerve 
segments under regenerating and degenerating conditions are evident. In the crushed 
nerve segments, first small diameter and thin myelinated axon profiles are detectable and 
indicate that the regeneration phase has been initiated between day 7 and 14 post injury. 
In contrast, distal segments under degenerating conditions display almost no more 
degenerating axons profiles, only few onion bulb like structures of degenerated myelinated 
axons are left. But also no regenerating axon profiles like in the crushed nerve are 
detectable. 
Upon final analysis, 28 days after injury, (Figure 7, E, J), differences between the 
regenerating and degenerating nerve segments are preserved. In the crushed nerve not 
only the number of regenerating axon profiles is increased, but also the diameter and 
myelin sheath thickness of the regenerating axons. This is indicative for the phase of fibre 
maturation. In contrast, under degenerating condition, the phase of chronic denervation is 
reflected by the completed clearance of myelin and the presence of dedifferentiated SC 
with no more phagocytic properties.  
 
MBP protein expression reflects different nerve regeneration stages 
 The analysis of the myelin basic protein (MBP) expression (Figure 8), both at mRNA 
and protein level, was utilized as a measure of myelination in distal nerve segments under 
regenerating and degenerating conditions.  
MBP mRNA level (Figure 8A) strongly decreases (p<0.001) after injury 
demonstrating lowest expression levels from day-3 to day-7. This reflects the phase of 
Wallerian degeneration also detectable on a morphological level (Figure 7B, C, G, H). In 
the following, MBP mRNA levels are up-regulated towards healthy control nerve levels 
under regenerating conditions. Reflecting the phases of axonal regrowth and maturation 
which are again also detectable on a morphological level (Figure 7D), healthy control 
values are already almost reached at day-14 after injury in distal segments of crushed 
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nerves, while this is not detected before day-28 after end-to-end repair. The latter finding 
indicates that axonal regrowth and maturation as well as remyelination are delayed after 
end-to-end repair in comparison to crush injuries. Under degenerating conditions, 
however, MBP mRNA levels remain strongly down-regulated, reflecting the entry into the 
morphologically detectable phase of chronic denervation (Figure 7I, J). 
MBP protein expression level (Figure 8B) again reflects the morphologically evident 
phases although its decrease demonstrates a lower kinetic. Under regenerating conditions 
at day-14, MBP protein is weakly expressed in distal segments of crushed nerves while 
the protein completely disappeared after end-to-end repair. In the following, the MBP 
protein expression level starts to recover towards healthy control nerve levels, displaying a 
delay after end-to-end repair compared to crush injury. Under degenerating conditions, 
MBP protein expression continuously disappeared from day-14 onward. 
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Discussion  
 
As summarized in Figure 9, the components of the NRG1/ErbB system are 
differentially regulated during the time course of peripheral nerve regeneration and 
degeneration. In the current study, three experimental conditions have been investigated 
with crush injury and end-to-end repair reflecting two regenerating conditions which 
demonstrate all phases from Wallerian degeneration over axonal regrowth to axonal 
maturation and remyelination following a different time course. In contrast, the unrepaired 
nerve reflected the degeneration condition represented by complete removal of peripheral 
myelin on morphological and protein level and no signs of axonal regrowth or 
remyelination in the chronic denervation phase. Differential regulation of the NRG1/ErbB 
system components on mRNA and protein levels can be specifically linked to the different 
phases of biomolecular and morphological changes the distal nerve segments undergo 
under regenerating and degenerating conditions.  
The NRG1/ErbB system is deeply involved in peripheral nerve myelination and 
remyelination processes and several previous studies by others and us focused on the 
role of soluble and transmembrane NRG1 isoforms in these late phases of nerve 
regeneration (Fricker & Bennett, 2011; Gambarotta et al., 2013). In particular, it has been 
shown that transmembrane type III NRG1 plays a key role both in myelination and 
remyelination (Michailov et al., 2004; Taveggia et al., 2005; Fricker et al., 2011; Stassart et 
al., 2013), while it has been suggested that soluble type I/II NRG1 is mainly involved in SC 
survival, redifferentiation and, therefore, in remyelination (Stassart et al., 2013). 
To our knowledge, this is the first time that mRNA expression levels also in the early 
phases after peripheral nerve injury were discriminated between not only soluble and 
transmembrane isoforms - which are involved in autocrine/paracrine and juxtacrine 
interactions - but also between type alpha and type beta isoforms - which are 
characterized by different activity - and between type a, type b and type c isoforms - which 
differ for the cytoplasmic C-terminal domain involved in NRG1 back signalling.   
We demonstrate here that NRG1 isoforms are differentially regulated after nerve 
injury, where we detected a strong increase of mRNA of the NRG1 type I/II, alpha and 
beta, as well as type a and type b at day-1. Therefore, we hypothesize that the observed 
NRG1 expression peak corresponds to different combinations of NRG1 type I/II, alpha and 
beta, a and b. A strong increase of soluble NRG1 expression at day-1 after nerve injury 
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was already described (Stassart et al., 2013) as well as the up-regulation of NRG1 alpha 
by others and us (Carroll et al., 1997; Nicolino et al., 2003).  
Alpha and beta NRG1 isoforms are known to differ in their activity, with alpha 
isoforms being about 10 fold less active than beta isoforms (Pinkas-Kramarski et al., 
1996). However, the difference between alpha and beta isoforms seems to be not only 
quantitative, but also qualitative. Indeed, it has been shown that NRG1 alpha and beta 
differentially affect the migration and invasion of malignant peripheral nerve sheath tumor 
cells (Eckert et al., 2009) and that NRG1 alpha is able to regulate genes involved in 
phosphorylation, acetylation and alternative splicing in lymphoblastoid cells (Ghahramani-
Seno et al., 2013). The concomitant up-regulation of both the NRG1 alpha and beta 
isoforms demonstrated in this study indicates that both play a regulatory role following 
peripheral nerve injury.   
The C-terminal domain of NRG1 (which can be type a, type b or type c) is a domain 
common to all soluble and transmembrane NRG1 isoforms, except NRG1 β3, and it is 
involved in the back signalling mediated by transmembrane NRG1 isoforms following 
interaction with ErbB receptors. Indeed, it has been demonstrated that, following 
NRG1/ErbB interaction, a γ-secretase cleavage releases a NRG1 intracellular domain 
(ICD) that translocates into the nucleus and, according to the cell model analysed, 
represses the expression of genes regulating  apoptosis (Bao et al., 2003), up-regulates 
the expression of postsynaptic density protein-95 (PSD-95) (Bao et al., 2004) and the 
expression of prostaglandin D2 synthase (L-PGDS) which, together with the G protein–
coupled receptor Gpr44, is involved in peripheral nerve myelination (Trimarco et al., 2014). 
We observed here a transient up-regulation of NRG1 isoforms containing type a and type 
b C-terminal ends, whereas the type c isoforms stably decrease after nerve injury. Further 
studies are necessary to investigate the role of type a, b, and c NRG1 isoforms both during 
development of the peripheral nervous system and after nerve injury. 
At the protein level, we analysed NRG1 expression using two antibodies, one 
directed to the cytoplasmic N-terminus common to all transmembrane type III NRG1, and 
one directed to the type a NRG1 C-terminus which can be present both in transmembrane 
type III NRG1 and in the transmembrane precursors of soluble type I/II NRG1. The most 
interesting data were obtained with the first antibody.  
After peripheral nerve injury we observed a “switch on” of a 100 kDa band, 
expressed also by SC, and a “switch-off” of the same 28 days after injury under 
  
21 
regenerating conditions, while it remained to be expressed in the degenerating condition, 
as previously described (Carroll et al., 1997). The high molecular weight of the band 
suggests that it is a full length type III NRG1, isoform b or c (not a, because the antibody 
directed to the type a domain did not detect it). The protein expression pattern suggests 
that this isoform plays a crucial role for nerve regeneration.  
Transmembrane NRG1 is usually considered to be expressed by axons and we 
demonstrate in this study that this expression is related to the phase of axonal regrowth.  
Nevertheless, its strong and stable expression observed also in the degenerating nerve 
and in SC suggests that this transmembrane isoform is of glial origin or potentially 
translated in the axon from previously transcribed mRNA. The latter hypothesis can be 
concluded from our NRG1 type III mRNA analysis that is not changed under regenerating 
conditions, while slightly increased (with a high standard error) in the degenerating nerve.   
Intriguingly, we observed the presence of a band with a molecular weight around 75 
kDa, whose weight slightly increases after injury. We hypothesized that this small increase 
could be due to a switch between ADAM17/TACE to BACE1 proteolytic cleavage of type 
III NRG1.  
It has been previously shown by others that products resulting from ADAM17/TACE 
cleavage of type III NRG1 inhibit remyelination (La Marca et al., 2011), while products 
resulting from BACE1 cleavage promote myelination (Willem et al., 2006). On the other 
hand, it has recently been shown that products resulting from BACE1 cleavage are not 
essential for the activation of myelination probably because additional proteases can also 
process NRG1 type III (Velanac et al., 2012). 
To our knowledge, the data in this study evidence, for the first time, a switch 
between the two cleavage activities of ADAM17/TACE and BACE1 following peripheral 
nerve injury in vivo. Our data show that the healthy nerve expresses only the α-N-terminal-
Fragment (α-NTF) of NRG1, which is the product of ADAM17/TACE cleavage, while 
regenerating nerves after end-to-end repair express only β-NTF, the product of the BACE1 
cleavage which promotes remyelination. In contrast, regenerating nerves after a milder 
injury (crush) express both α-NTF and β-NTF of NRG1, suggesting that in this model 
axonal regrowth and remyelination phases are partially overlapping. Finally, 4-weeks after 
injury regenerating nerves express only α-NTF, indicating that remyelination is completed 
at that time after a crush injury as well as after end-to-end repair. Under degenerating 
  
22 
conditions β-NTF is still expressed 28 days after injury, indicating that the machinery is 
kept on “stand-by” for eventually still regrowing axons. 
As after axonotmesis (crush) and neurotmesis (transection and repair or non-
repaired),  the continuity between distal axons and the corresponding cell bodies is 
disrupted, it is very likely that the NRG1 β-NTF band we observe after nerve injury is 
locally synthesized in the analysed nerve segments. This hypothesis is strengthened by 
data demonstrating that peripheral nerves contain mRNA, ribosomal proteins and Golgi-
like structures and that local translation can occur in the injured nerve (Yoo et al., 2010). 
Intriguingly, intercellular transport of ribosomes (Court et al., 2011) and mRNA (Giuditta et 
al., 2002; Sotelo et al., 2014) from SC to axons has been demonstrated before. The latter 
reinforces the idea that SC may support local axonal protein synthesis.  
In order to assign the 75 kDa C-terminal fragment (CTF) band to specific NRG1 
isoforms, the following conclusions can be drawn from our data. NRG1 protein expression 
levels were analysed with one antibody directed against the cytoplasmic NRG1 C-terminus 
which is shared by all isoforms containing the exon defining type a isoforms. Therefore, 
the 75 kDa CTF can derive either from the proteolytic cleavage of the transmembrane type 
III NRG1 isoforms or the proteolytic cleavage of the pro-protein type I/II isoforms (which 
are transmembrane, but release an extracellular soluble fragment, leaving a membrane 
anchored C-terminus). 
  However, because we observed two different molecular weights for the N-terminal 
fragment of NRG1 with the AB5551 antibody directed to the type III NRG1 (α-NTF and β-
NTF), and only a single band with the sc-348 antibody directed to the C-terminal fragments 
of NRG1 (α-CTF and β-CTF) we hypothesize that this band corresponds to the CTF 
derived from the proteolytic cleavage of the precursor of type I/II NRG1 type a isoform. 
The two bands of type III NRG1 isoforms observed with the AB5551 antibody must then 
represent type b or type c isoforms.  
With regard to the NRG1 signalling after peripheral nerve injury, we also analysed 
the expression of ErbB receptors again both at mRNA and protein level.  
Under regenerating conditions ErbB2 and ErbB3 mRNA levels show a down-
regulation at day-1 after injury, followed by a strong up-regulation of ErbB3 while ErbB2 
mRNA level decreases to constant low levels. At the protein level, the regenerating 
condition is reflected by an initial decrease of ErbB1 and ErbB3 protein followed by a 
strong up-regulation of ErbB1-3. Until the end of the observation period, ErbB1 and ErbB2 
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proteins are down-regulated again in the regenerating nerve samples at day-28 after 
injury, although their expression is still higher than control.  
Under degenerating conditions, ErbB1 and ErbB2 mRNA expression is constantly 
comparable to the control during all time points analysed, while the initially down-regulated 
ErbB3 mRNA level increases at day-7 after injury and remains highly up-regulated until 
day-28. At the protein level, ErbB1 expression is constantly increased under degenerating 
conditions, while the protein expression patterns of ErbB2 and ErbB3 are similar those 
under regenerating conditions. Our data obtained in the degenerating nerve are consistent 
with a previous study of ErbB and NRG1 expression during Wallerian degeneration after 
sciatic nerve transection injury (Carroll et al., 1997). 
The strong up-regulation of ErbB2 protein in the early phase after injury is 
independent of the repair conditions provided and does not correspond to an mRNA 
expression level increase. We confirm, however, that the ErbB2 transcript level is stably 
high in the analysis of the threshold cycle by real time PCR. Therefore, it is very likely that 
the strong protein up-regulation after nerve injury is the consequence of post-
transcriptional regulation occurring through different signal transduction pathways.  Indeed, 
different research groups analysed already the expression of microRNAs and their role in 
post-transcriptional regulation following nerve injury (Viader et al., 2011; Wu et al., 2011; 
Chang et al., 2013; Nagata et al., 2014; Zhou et al., 2014). And, the injury induced down-
regulation of microRNAs having ErbB2 and ErbB3 as target genes could contribute to 
ErbB2 and ErbB3 protein up-regulation (Scott et al., 2007). Moreover, post-transcriptional 
regulation could be the consequence of protein kinase A (PKA) activation occurring after 
nerve injury. Related to this hypothesis, it has been demonstrated in vitro that NRG1 and 
forskolin synergize and that forskolin increases ErbB2-ErbB3 protein expression in human 
SC without increasing levels of mRNA encoding these receptors (Fregien et al., 2005). 
Forskolin activates the enzyme adenylyl cyclase thus increasing intracellular levels of 
cyclic adenosine monophosphate (cAMP), an important second messenger that acts by 
activating cAMP-sensitive pathways such as PKA. Therefore, the activation of cAMP 
signalling, which has also been shown to synergize with NRG1 in the promotion of 
myelination (Arthur-Farraj et al., 2011), could contribute to ErbB2 protein up-regulation.  
The regulation of NRG1 and ErbB mRNA expression we observed in the 
degenerating nerve in vivo was confirmed also in vitro, suggesting that the corresponding 
genes are expressed by cells resident inside the nerve. 
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Finally, we analysed AKT and ERK phosphorylation to investigate the existence of 
possible differences in the signal transduction pathways activated in response to the 
regenerating or degenerating conditions after peripheral nerve injury. AKT is more 
phosphorylated in the end-to-end repaired and degenerating samples, suggesting that it is 
involved in the response to more severe injuries. ERK signalling was already described 
before to be rapidly and strongly activated following nerve injury (Sheu et al., 2000; 
Harrisingh et al., 2004; Napoli et al., 2012). Our data obtained from the current study, 
however, do not display any differences among the regenerating and degenerating 
conditions during the observation period. With high levels of phosphorylated ERK at day-1 
after injury and its disappearance at day-28 it is likely that the role of ERK is more linked to 
the general response of the nerve after injury than to regeneration or degeneration.  
 
Conclusion 
We demonstrate here that the components of the NRG1/ErbB system are differently 
regulated in the different phases a peripheral nerve undergoes after injury with the aim to 
regenerate. The immediate response to nerve injury is represented by ERK 
phosphorylation and by the up-regulation of soluble NRG1 (type alpha and beta, type a 
and b), which suggests that soluble NRG1 isoforms are involved in the response to nerve 
injury, stimulating SC survival and promoting axon regrowth. One week after injury, 
expression of ErbB2/ErbB3 co-receptor also is strongly up-regulated. 
We additionally identified a highly expressed type III NRG1 100 kDa isoform, the 
expression of which is only switched off after axon regeneration.  
 Furthermore, our data suggest the existence of a reversible switch between 
ADAM17/TACE and BACE1 cleavage activity of type III NRG1 following nerve injury, 
which is very likely needed for the regulation of the remyelination process.  
Moreover, we demonstrate here for the first time the involvement of type a, b and c 
isoforms in peripheral nerve regeneration. Further studies will be necessary to better 
understand their role in the back signalling mediated by NRG1. 
The precise regulation of the components of the NRG1/ErbB system indicates that 
each molecule that undergoes changes on the mRNA and protein level is crucially 
involved in successful peripheral nerve regeneration and could be a target for pre-clinical 
evaluation of regeneration promoting factors. 
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Abbreviations 
 
A disintegrin and metalloprotease (ADAM17) 
Cyclic adenosine monophosphate (cAMP) 
β-site of amyloid precursor protein-cleaving enzyme1 (BACE1) 
C-terminal fragment (CTF) 
Dulbecco's Modified Eagle Medium (DMEM) 
Epidermal Growth Factor (EGF) 
Foetal bovine serum (FBS) 
Intracellular domain (ICD) 
Lipocalin-type prostaglandin D2 synthase (L-PGDS)  
Myelin basic protein (MBP) 
Neuregulin1 (NRG1) 
N-terminal fragment (NTF) 
Peripheral Nervous System (PNS) 
Phosphatydil-inositol-3 kinase (PI3K) 
Protein kinase A (PKA) 
Schwann cells (SC) 
Tumour necrosis factor-α-converting enzyme (TACE) 
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Figure legends 
 
Table I: Primers used for quantitative real time PCR analysis. The name of the 
amplified gene or isoform is indicated in the first column, followed by the accession 
number to reference sequences. The primer name indicates if the primers anneals only to 
Rattus norvegicus sequences (r) or also to Mus musculus (m).  
 
Figure 1: ErbB mRNA is highly regulated after nerve injury. The relative quantification 
(-ΔΔCt) of ErbB1, ErbB2 and ErbB3 receptor was obtained by quantitative real-time PCR: 
data were normalized to the geometric mean of two endogenous housekeeping genes 
(ANKRD27 and RICTOR). Values in the graphics are expressed as mean ± SEM. 
Statistical analysis (one-way ANOVA with Bonferroni’s post hoc) was carried out to 
compare the differences among the three injury models at each time point. Asterisks (*) 
denote statistically significant differences between crush and end-to-end repair conditions; 
dollars ($) between crush and degenerating nerves conditions; hashes (#) between end-to-
end repair and degenerating nerve conditions (*/$/#: p ≤ 0.05, **/$$/##: p ≤ 0.01 and 
***/$$$/###: p ≤ 0.001). Statistical analysis of the comparison of each time point with 
control condition is discussed in the text. 
 
Figure 2: NRG1 soluble isoforms are strongly up-regulated at mRNA level 
immediately after nerve injury. The relative quantification (-ΔΔCt) of NRG1 type I/II, 
NRG1 type III, NRG1α and NRG1β was obtained by quantitative real-time PCR: data were 
normalized to the geometric mean of two endogenous housekeeping genes (ANKRD27 
and RICTOR). Values in the graphics are expressed as mean ± SEM. Statistical analysis 
(one-way ANOVA with Bonferroni’s post hoc) was carried out to compare the differences 
among the three injury models at each time point. Asterisks (*) denote statistically 
significant differences between crush and end-to-end repair conditions; dollars ($) between 
crush and degenerating nerves conditions; hashes (#) between end-to-end repair and 
degenerating nerve conditions (*/$/#: p ≤ 0.05, **/$$/##: p ≤ 0.01 and ***/$$$/###: p ≤ 
0.001). Statistical analysis of the comparison of each time point with control condition is 
discussed in the text. 
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Figure 3: NRG1 type a and type b isoforms are up-regulated at mRNA level after 
nerve injury. The relative quantification (-ΔΔCt) of NRG1 type a, type b and type c was 
obtained by quantitative real-time PCR: data were normalized to the geometric mean of 
two endogenous housekeeping genes (ANKRD27 and RICTOR). Values in the graphics 
are expressed as mean ± SEM. Statistical analysis (one-way ANOVA with Bonferroni’s 
post hoc) was carried out to compare the differences among the three injury models at 
each time point. Asterisks (*) denote statistically significant differences between crush and 
end-to-end repair conditions; dollars ($) between crush and degenerating nerves 
conditions; hashes (#) between end-to-end repair and degenerating nerve conditions 
(*/$/#: p ≤ 0.05, **/$$/##: p ≤ 0.01 and ***/$$$/###: p ≤ 0.001). Statistical analysis of the 
comparison of each time point with control condition is discussed in the text. 
 
Figure 4: NRG1/ErbB expression in in vitro degenerating nerves. Nerves were 
cultured for 1 day. This in vitro experimental procedure mimics in vivo nerve degeneration. 
The relative quantification (-ΔΔCt) of NRG1/ErbB was obtained by quantitative real-time 
PCR: data were normalized to the geometric mean of two endogenous housekeeping 
genes (ANKRD27 and RICTOR). Values in the graphics are expressed as mean + SEM. 
One-way ANOVA with Bonferroni’s post hoc was used for statistical analysis (*: p ≤ 0.05, 
**: p ≤ 0.01 and ***: p ≤ 0.001). 
 
Figure 5:  ErbB receptor proteins are deeply regulated in the three experimental 
injury models. Western blot analysis of proteins extracted from healthy nerves (0) and 
distal segments of injured nerves at different time points, separated on 8% gels (50 μg/ 
lane) and probed with antibodies for ErbB1, ErbB2, ErbB3, p-AKT, total-AKT, p-ERK, total-
ERK, MBP, GAPDH, β-actin. The same samples were run on three independent gels to 
analyse the expression of different proteins characterized by the same molecular weight. 
The positions of the detected proteins is indicated on the left, size markers on the right.  
The band corresponding to the phosphorylated AKT is detectable between two unspecific 
bands. Its identification was possible by comparison with the band corresponding to the 
total AKT protein.  
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Figure 6: NRG1 isoforms are deeply regulated at protein level in the three 
experimental injury models. Western blot analysis of proteins extracted from healthy 
nerves (0) and from the distal segment of injured nerves at different time points. Proteins 
(50 μg/lane) were separated on 4-15% gels. In the panel A proteins were probed with an 
antibody (AB5551) directed to the N-terminus of all type III NRG1 isoforms. This antibody 
recognizes: a 100 kDa band (detected also in adult primary Schwann cells-SC) whose 
expression switch on after injury and off after regeneration, but remains on in the 
degenerating nerve; a pair of bands about 75 kDa which would correspond to the N-
terminus fragments (NTF) resulting from α (ADAM17/TACE) or β (BACE) secretase 
cleavage of type III NRG1 (α–NTF, β-NTF); some bands around 50kDa, whose expression 
seems to be regulated following injury, but whose identity is currently unclear. In the panel 
B the same samples were probed with an antibody (sc348) directed to the type a C-
terminus common to many NRG1 isoforms. This antibody recognizes only a 75 kDa band 
which would correspond to the C-terminus fragment (CTF) resulting from the cleavage of 
type a NRG1 isoforms (both soluble and transmembrane). The positions of the detected 
proteins is indicated on the left, size markers are indicated on the right. In the panel C a 
very simplified structure of type I/II soluble isoforms and type III transmembrane isoforms 
of NRG1 is schematized, together with antibody epitope. This scheme illustrates that type 
I/II and type III isoforms differ for the N-terminus regions, that the CTF can derive from 
both type I/II and type III NRG1 isoform cleavage, and that CTF can be recognized by sc-
348 only if its C-terminal end is type a. ADAM17/TACE and BACE1 cleavage sites on type 
III NRG1 are shown, to illustrate how the NTF fragment produced by the BACE1 cleavage 
(β-NTF) has a molecular weight higher than the NTF fragment produced by the 
ADAM17/TACE (α–NTF) cleavage. 
 
Figure 7: Representative electron micrographs of transverse median nerve sections 
of crushed nerve (A;B;C;D;E) and degenerating nerve (F;G;H;I;J) after 1 day (A;F), 3 
days (B;G), 7 days (C;H), 14 days (D;I) and 28 days (E;J) from the injury. 1 day, 3 days 
and 7 days after injury, nerve morphology appears similar in both experimental models: 1 
day after injury (A,F), partially de-compacted myelin sheaths (white asterisks) are visible; 
after 3 days (B,G), increasing amount of connective tissue can be appreciated, as well as 
detached myelin lamellae (white asterisks). 7 days after injury (C, H), almost all nerve 
fibres display degeneration: collapsed axon with disintegrated myelin sheath (white 
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asterisks) and the dedifferentiated SC with phagocytotic properties (white arrow head) are 
detected. 15 days after injury, differences between regenerating and degenerating nerves 
are evident: in the crushed nerve (D) small diameter regenerating axons with thin myelin 
(some fibres are indicated with black asterisks in the figure) are detected, whereas under 
degenerating condition (I) onion bulbs can be still seen (white asterisks). Finally, after 28 
days, regenerating axon profiles with increased diameter and myelin sheaths are detected 
in crush injury group (E), while under degenerating conditions, dedifferentiated SC without 
vacuoles are present in the nerve distal segment (white asterisks, J). Scale bar: 5 µm 
 
Figure 8: MBP expression reflects the nerves regenerating and degenerating 
conditions. The relative quantification (-ΔΔCt) of MBP (A) was obtained by quantitative 
real-time PCR: data were normalized to the geometric mean of two endogenous 
housekeeping genes (ANKRD27 and RICTOR). Values in the graphics are expressed as 
mean ± SEM. One-way ANOVA was used for statistical analysis with */$/#: p ≤ 0.05, 
**/$$/##: p ≤ 0.01 and ***/$$$/###: p ≤ 0.001 in order to compare the differences among 
the three model of injury at each time point. Asterisks (*) denote statistically significant 
differences between crush and end-to-end repair conditions; dollars ($) between crush and 
degenerating nerve conditions; hashes (#) between end-to-end repair and degenerating 
nerve conditions (*/$/#: p ≤ 0.05, **/$$/##: p ≤ 0.01 and ***/$$$/###: p ≤ 0.001). Statistical 
analysis of the comparison of each time point with control condition is discussed in the 
text. Western blot analysis (B) showing MBP expression in the three injury models. β-actin 
and GAPDH were used as a loading control. 
 
Figure 9: Schematic representation of all mRNA and protein data shown in this 
paper. Upward and downward arrows represent up-regulation and down-regulation 
respectively. This graphical representation is not intended to exactly indicate the beginning 
and the ending of the three phases occurring after nerve injury (nerve degeneration, axon 
growth and remyelination), but rather the period when each process mainly occurs.    
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